Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 15/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 6/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.45 |
| ▸ | NCOR2 | Q9Y618 | 4/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 14/20 | 0.39 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.36 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.34 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14238036 | 0.85 | HDAC1 (0.46) | HDAC1HDAC3HDAC2NCOR2HDAC6 | |
| SCHEMBL1853715 | 0.81 | HDAC1 (0.50) | HDAC1HDAC3HDAC2NCOR2HDAC6 | |
| SCHEMBL5846695 | 0.81 | HDAC1 (0.43) | HDAC1HDAC3HDAC2NCOR2HDAC6 | |
| SCHEMBL4950941 | 0.81 | HDAC1 (0.46) | HDAC1HDAC3HDAC2NCOR2SSTR4 | |
| SCHEMBL5846696 | 0.78 | HDAC1 (0.41) | HDAC1HDAC3HDAC2NCOR2HDAC6 | |
| SCHEMBL4948320 | 0.77 | HDAC3 (0.40) | HDAC1HDAC3HDAC2NCOR2SSTR4 | |
| SCHEMBL4948328 | 0.77 | NSD2 (0.41) | HDAC1HDAC3HDAC2NCOR2SSTR4 | |
| SCHEMBL14090105 | 0.76 | HDAC1 (0.39) | HDAC1HDAC3HDAC2NCOR2SSTR4 | |
| SCHEMBL5884593 | 0.75 | HDAC1 (0.53) | HDAC1HDAC3HDAC2NCOR2HDAC6 | |
| SCHEMBL2773953 | 0.75 | HDAC1 (0.41) | HDAC1HDAC3HDAC2NCOR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200535-A1 | sphingosine 1-phosphate-1/EDG-1 receptor agonists; autoimmune diseases; immunosuppressants by inducing lymphocyte sequestration in secondary lymphoid tissues; 4-aminocyclopentane-2-encarboxylic acid hydrochloric acid salt | ASAHI KASEI PHARMA CORPORATION (JP) | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200535-A1 | sphingosine 1-phosphate-1/EDG-1 receptor agonists; autoimmune diseases; immunosuppressants by inducing lymphocyte sequestration in secondary lymphoid tissues; 4-aminocyclopentane-2-encarboxylic acid hydrochloric acid salt | S1PR1, S1PR2, S1PR4 | HDAC1 1133/4885HDAC3 2886/4885HDAC2 1722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.